SARS-CoV-2入胞机制的研究进展
Research Progress on the Mechanism of SARS-CoV-2 Entry into Cells
DOI: 10.12677/AMB.2023.121002, PDF,    国家科技经费支持
作者: 袁小枚*, 王 嘉#：汕头大学医学院，广东 汕头；李利峰：香港大学医学院，香港
关键词: SARS-CoV-2；S蛋白；受体；水解激活；膜融合；入胞；SARS-CoV-2； S Protein； Receptor； Activation by Hydrolysis； Fusion of Membrane； Entry of Cell
摘要: 新冠病毒(SARS-CoV-2)大流行对全球的公共卫生及经济造成了前所未有的影响，有关它的研究也成为了当前科学界最热门的领域之一；作为病毒感染的首要环节，SARS-CoV-2的入胞机制更成为人们认识病毒行为、研究阻断病毒入侵途径的关注点。本文对SARS-CoV-2进入细胞过程中涉及的蛋白、受体、辅助因子、入胞过程中的S蛋白构象变化、入胞途径等进行了全面综述，以期展示SARS-CoV-2的入胞条件与动态图谱，为明晰病毒与细胞的相互作用、研制疫苗或治疗药物奠定基础。
Abstract: The novel coronavirus pandemic made great impact on both public health and economy, and thus became one of the major hotspots in research. As the primary step of infection, how SARS-CoV-2 viruses enter the host cells is the key to understand the viral behavior and also crucial for blocking the virus infection. To illustrate the cell entry process, the proteins, receptors, cofactors, conformational changes of S proteins and pathways involved in the entry process of SARS-CoV-2 into cells were comprehensively reviewed. The perspicuity on cellular entry conditions and viral dynamic change during this process helps to understand the virus-cell interaction and lays fundation for vaccines and therapeutic drugs development.
文章引用：袁小枚, 李利峰, 王嘉. SARS-CoV-2入胞机制的研究进展[J]. 微生物前沿, 2023, 12(1): 10-17. https://doi.org/10.12677/AMB.2023.121002

参考文献

[1] Wang, C., Horby, P.W., Hayden, F.G., et al. (2020) A Novel Coronavirus Outbreak of Global Health Concern. The Lancet, 395, 470-473. [Google Scholar] [CrossRef] 
[2] Kim, D., Lee, J.Y., Yang, J.S., et al. (2020) The Architecture of SARS-CoV-2 Transcriptome. Cell, 181, 914-921.e10. [Google Scholar] [CrossRef] [PubMed]
[3] Lv, Z., Deng, Y.Q., Ye, Q., et al. (2020) Structural Basis for Neutralization of SARS-CoV-2 and SARS-CoV by a Potent Therapeutic Antibody. Science, 369, 1505-1509. [Google Scholar] [CrossRef] [PubMed]
[4] Wang, X., Cao, R., Zhang, H., et al. (2020) The Anti-Influenza Virus Drug, Arbidol Is an Efficient Inhibitor of SARS-CoV-2 in Vitro. Cell Discovery, 6, 28. [Google Scholar] [CrossRef] [PubMed]
[5] De Vries, R.D., Schmitz, K.S., Bovier, F.T., et al. (2021) Intranasal Fusion Inhibitory Lipopeptide Prevents Direct-Contact SARS-CoV-2 Transmission in Ferrets. Science, 371, 1379-1382. [Google Scholar] [CrossRef] [PubMed]
[6] Xia, S., Liu, M., Wang, C., et al. (2020) Inhibition of SARS-CoV-2 (Previously 2019-nCoV) Infection by a Highly Potent Pan-Coronavirus Fusion Inhibitor Targeting Its Spike Protein That Harbors a High Capacity to Mediate Membrane Fusion. Cell Research, 30, 343-355. [Google Scholar] [CrossRef] [PubMed]
[7] Ling, R., Dai, Y., Huang, B., et al. (2020) In Silico Design of Antiviral Peptides Targeting the Spike Protein of SARS- CoV-2. Peptides, 130, Article ID: 170328. [Google Scholar] [CrossRef] [PubMed]
[8] Hoffmann, M., Schroeder, S., Kleine-Weber, H., et al. (2020) Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19. Antimicrobial Agents and Chemotherapy, 64, e00754-20. [Google Scholar] [CrossRef] 
[9] Hoffmann, M., Kleine-Weber, H., Schroeder, S., et al. (2020) SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 181, 271-280.e8. [Google Scholar] [CrossRef] [PubMed]
[10] Cheng, Y.W., Chao, T.L., Li, C.L., et al. (2020) Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects. Cell Reports, 33, Article ID: 108254. [Google Scholar] [CrossRef] [PubMed]
[11] Benton, D.J., Wrobel, A.G., Xu, P., et al. (2020) Receptor Binding and Priming of the Spike Protein of SARS-CoV-2 for Membrane Fusion. Nature, 588, 327-330. [Google Scholar] [CrossRef] [PubMed]
[12] Walls, A.C., Park, Y.J., Tortorici, M.A., et al. (2020) Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell, 181, 281-292 e6. [Google Scholar] [CrossRef] [PubMed]
[13] Xu, X., Li, G., Sun, B., et al. (2022) S2 Subunit of SARS-CoV-2 Spike Protein Induces Domain Fusion in Natural Pulmonary Surfactant Monolayers. The Journal of Physical Chemistry Letters, 13, 8359-8364. [Google Scholar] [CrossRef] [PubMed]
[14] Chambers, P., Pringle, C.R. and Easton, A.J. (1990) Heptad Repeat Sequences Are Located Adjacent to Hydrophobic Regions in Several Types of Virus Fusion Glycoproteins. Journal of General Virology, 71, 3075-3080. [Google Scholar] [CrossRef] [PubMed]
[15] Kumar, S., Maurya, V.K., Prasad, A.K., et al. (2020) Structural, Glycosylation and Antigenic Variation between 2019 Novel Coronavirus (2019-nCoV) and SARS Coronavirus (SARS-CoV). VirusDisease, 31, 13-21. [Google Scholar] [CrossRef] [PubMed]
[16] Tang, T., Bidon, M., Jaimes, J.A., et al. (2020) Coronavirus Membrane Fusion Mechanism Offers a Potential Target for Antiviral Development. Antiviral Research, 178, Article ID: 104792. [Google Scholar] [CrossRef] [PubMed]
[17] Xia, X. (2021) Domains and Functions of Spike Protein in Sars-Cov-2 in the Context of Vaccine Design. Viruses, 13, 109. [Google Scholar] [CrossRef] [PubMed]
[18] Coutard, B., Valle, C., De Lamballerie, X., et al. (2020) The Spike Glycoprotein of the New Coronavirus 2019-nCoV Contains a Furin-Like Cleavage Site Absent in CoV of the Same Clade. Antiviral Research, 176, Article ID: 104742. [Google Scholar] [CrossRef] [PubMed]
[19] Yan, R., Zhang, Y., Li, Y., et al. (2020) Structural Basis for the Recognition of SARS-CoV-2 by Full-Length Human ACE2. Science, 367, 1444-1448. [Google Scholar] [CrossRef] [PubMed]
[20] Wu, L., Chen, Q., Liu, K., et al. (2020) Broad Host Range of SARS-CoV-2 and the Molecular Basis for SARS-CoV-2 Binding to Cat ACE2. Cell Discovery, 6, 68. [Google Scholar] [CrossRef] [PubMed]
[21] Liu, K., Tan, S., Niu, S., et al. (2021) Cross-Species Recognition of SARS-CoV-2 to Bat ACE2. Proceedings of the National Academy of Sciences of the United States of America, 118, e2020216118. [Google Scholar] [CrossRef] [PubMed]
[22] Peng, R., Wu, L.A., Wang, Q., et al. (2021) Cell Entry by SARS-CoV-2. Trends in Biochemical Sciences, 46, 848-860. [Google Scholar] [CrossRef] [PubMed]
[23] Jackson, C.B., Farzan, M., Chen, B., et al. (2022) Mechanisms of SARS-CoV-2 Entry into Cells. Nature Reviews Molecular Cell Biology, 23, 3-20. [Google Scholar] [CrossRef] [PubMed]
[24] Daly, J.L., Simonetti, B., Klein, K., et al. (2020) Neuropilin-1 Is a Host Factor for SARS-CoV-2 Infection. Science, 370, 861-865. [Google Scholar] [CrossRef] [PubMed]
[25] Cantuti-Castelvetri, L., Ojha, R., Pedro, L.D., et al. (2020) Neuropilin-1 Facilitates SARS-CoV-2 Cell Entry and Infectivity. Science, 370, 856-860. [Google Scholar] [CrossRef] [PubMed]
[26] Davanzo, G.G., Codo, A.C., Brunetti, N.S., et al. (2020) SARS-CoV-2 Uses CD4 to Infect T Helper Lymphocytes.
[27] Wang, S., Qiu, Z., Hou, Y., et al. (2021) AXL Is a Candidate Receptor for SARS-CoV-2 That Promotes Infection of Pulmonary and Bronchial Epithelial Cells. Cell Research, 31, 126-140. [Google Scholar] [CrossRef] [PubMed]
[28] Wang, K., Chen, W., Zhang, Z., et al. (2020) CD147-Spike Protein Is a Novel Route for SARS-CoV-2 Infection to Host Cells. Signal Transduction and Targeted Therapy, 5, 283. [Google Scholar] [CrossRef] [PubMed]
[29] Gu, Y., Cao, J., Zhang, X., et al. (2022) Receptome Profiling Identifies KREMEN1 and ASGR1 as Alternative Functional Receptors of SARS-CoV-2. Cell Research, 32, 24-37. [Google Scholar] [CrossRef] [PubMed]
[30] Hänel, K. and Willbold, D. (2007) SARS-CoV Accessory Protein 7a Directly Interacts with Human LFA-1. Biological Chemistry, 388, 1325-1332. [Google Scholar] [CrossRef] 
[31] Shen, X.R., Geng, R., Li, Q., et al. (2022) ACE2-Independent Infection of T Lymphocytes by SARS-CoV-2. Signal Transduction and Targeted Therapy, 7, 83. [Google Scholar] [CrossRef] [PubMed]
[32] Matsuyama, S. and Taguchi, F. (2009) Two-Step Conformational Changes in a Coronavirus Envelope Glycoprotein Mediated by Receptor Binding and Proteolysis. Journal of Virology, 83, 11133-11141. [Google Scholar] [CrossRef] 
[33] Kim, Y., Jang, G., Lee, D., et al. (2022) Trypsin Enhances SARS-CoV-2 Infection by Facilitating Viral Entry. Archives of Virology, 167, 441-458. [Google Scholar] [CrossRef] [PubMed]
[34] Ji, H.L., Zhao, R., Matalon, S., et al. (2020) Elevated Plasmin(ogen) as a Common Risk Factor for COVID-19 Susceptibility. Physiological Reviews, 100, 1065-1075. [Google Scholar] [CrossRef] [PubMed]
[35] Cohen, F.S. and Melikyan, G.B. (2004) The Energetics of Membrane Fusion from Binding, through Hemifusion, Pore Formation, and Pore Enlargement. The Journal of Membrane Biology, 199, 1-14. [Google Scholar] [CrossRef] [PubMed]
[36] Zhang, J., Cai, Y., Xiao, T., et al. (2021) Structural Impact on SARS-CoV-2 Spike Protein by D614G Substitution. Science, 372, 525-530. [Google Scholar] [CrossRef] [PubMed]
[37] Bestle, D., Heindl, M.R., Limburg, H., et al. (2020) TMPRSS2 and Furin Are both Essential for Proteolytic Activation of SARS-CoV-2 in Human Airway Cells. Life Science Alliance, 3, e202000786. [Google Scholar] [CrossRef] 
[38] Koch, J., Uckeley, Z.M., Doldan, P., et al. (2021) TMPRSS2 Expression Dictates the Entry Route Used by SARS- CoV-2 to Infect Host Cells. The EMBO Journal, 40, e107821. [Google Scholar] [CrossRef] [PubMed]
[39] Wang, P., Lau, S.Y., Deng, S., et al. (2021) Characterization of an Attenuated SARS-CoV-2 Variant with a Deletion at the S1/S2 Junction of the Spike Protein. Nature Communications, 12, 2790. [Google Scholar] [CrossRef] [PubMed]
[40] Johnson, B.A., Xie, X., Bailey, A.L., et al. (2021) Loss of Furin Cleavage Site Attenuates SARS-CoV-2 Pathogenesis. Nature, 591, 293-299. [Google Scholar] [CrossRef] [PubMed]
[41] Sasaki, M., Toba, S., Itakura, Y., et al. (2021) SARS-CoV-2 Bearing a Mutation at the S1/S2 Cleavage Site Exhibits Attenuated Virulence and Confers Protective Immunity. mBio, 12, e0141521. [Google Scholar] [CrossRef] 
[42] Peacock, T.P., Goldhill, D.H., Zhou, J., et al. (2021) The Furin Cleavage Site in the SARS-CoV-2 Spike Protein Is Required for Transmission in Ferrets. Nature Microbiology, 6, 899-909. [Google Scholar] [CrossRef] [PubMed]
[43] Sasaki, M., Uemura, K., Sato, A., et al. (2021) SARS-CoV-2 Variants with Mutations at the S1/S2 Cleavage Site Are Generated in Vitro during Propagation in TMPRSS2-Deficient Cells. PLOS Pathogens, 17, e1009233. [Google Scholar] [CrossRef] [PubMed]
[44] Liu, T., Luo, S., Libby, P., et al. (2020) Cathepsin L-Selective Inhibitors: A Potentially Promising Treatment for COVID-19 Patients. Pharmacology & Therapeutics, 213, Article ID: 107587. [Google Scholar] [CrossRef] [PubMed]

为你推荐